Adaptive Biotechnologies is a pioneer & leader in immune-driven medicine. We aim to improve lives by learning from the wisdom of our adaptive immune systems.
Seattle, WA. U.S.A.
Joined April 2012
- Tweets2.6K
- Following1.3K
- Followers4.5K
- Likes638
Adaptive Biotech retweeted
Your clonoSEQ #MRD reports are now available through MyChart, an online portal where you can view new and historical test results. Learn more: clonoseq.com/get-my-clonoseq…
clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: rb.gy/8tju9y
Adaptive Biotech retweeted
Ben Derman, MD presents strategies to discontinue maintenance therapy based on MRD negativity status in #MultipleMyeloma pts. This approach not only improves quality of life but saves a lot of money. #ASCO24
@bdermanmd @UCCancerCenter @UChicagoHemOnc
Adaptive Biotech retweeted
Earlier this month, LSW and @AdaptiveBiotech were joined by Sen. Javier Valdez, Rep. Larry Springer, and Rep. Cindy Ryu for a tour of Adaptive’s clinical and R&D labs. We discussed how they can help foster the next generation of #lifescience companies and support the #workforce.
Adaptive Biotech retweeted
This #CLL study used clonoSEQ to assess MRD in peripheral blood, as uMRD was one of its secondary endpoints.
FDA-cleared to measure MRD in MM, CLL, & B-ALL; CLIA-validated in other lymphoid cancers. Info on sample types & test limitations: rb.gy/8tju9y
CONGRESS | #ASH23 | Tanya Siddiqi @cityofhope presents 24-month median follow-up of TRANSCEND-CLL-004 of liso-cel for pts with R/R #CLL after ≥2 prior therapies including BTKi. N=118, primary endpoint met, CR/CRi rate=20%, ORR=44%, uMRD rate in blood=64%. Median DOR and median PFS not reached. #lymphoma #lymsm #leusm
Adaptive Biotech retweeted
Vincenzo Di Cerbo, will be part of a webinar with @AdaptiveBiotech on Weds 22nd Feb, on how a single-cell assay combined with high-throughput T-cell receptor sequencing can provide next gen solution for characterizing & tracking #celltherapies
bit.ly/3XIZk3W
Adaptive Biotech retweeted
At #ASH22, join @AdaptiveBiotech at this Product Theater: The clinical actionability of clonoSEQ MRD assessment in lymphoid malignancies. clonoSEQ is FDA-cleared to assess MRD in CLL, MM and B-ALL. For further info: rb.gy/8tju9y
Adaptive Biotech retweeted
Come by the @AdaptiveBiotech booth #930 to learn about clonoSEQ, ask questions about MRD, and meet our team. #ASH22 clonoSEQ is FDA-cleared to assess MRD in CLL, MM and B-ALL. For further info: rb.gy/8tju9y
Adaptive Biotech retweeted
In this webinar by @AdaptiveBiotech, learn about optimizing pre-clinical #drugdevelopment by decoding the genetic information stored in the adaptive immune system’s T- and B-cell receptors.
Register now. buff.ly/3gvGpIR
#MouseModel #ClinicalTrials
Adaptive Biotech retweeted
Looking forward to my presentation at #IO360NYC! I’ll be sharing an overview of the @AdaptiveBiotech immune medicine platform and how it can help inform immune-based therapies. Hope to see you there! Full agenda at adaptivebio.tech/bzt.
@conferenceforum #IO #ImmunoOncology
Adaptive Biotech retweeted
Wondering about vaccine and booster efficacy against Omicron and other COVID-19 variants? Former @US_FDA commissioner Andrew von Eschenbach and I on the critical need to measure the T cell response in @WSJ. rebrand.ly/fbaz1y3
Adaptive Biotech retweeted
Great article by @axios on the shift to studying T cell response to omicron. rebrand.ly/l8xd5bd
Adaptive Biotech retweeted
I’m excited to share the #HLTH2021 stage in Boston with leaders at @TCR2_Tx, @CardinalHealth and @VinetiWorks to discuss innovations in supply chain 2.0 to deliver personalized medicine. Tune in on Oct. 19 at 9:20 a.m. EDT.
Register at rebrand.ly/469h5x0.
Adaptive Biotech retweeted
Brothers Chad and Harlan Robins, founders of @AdaptiveBiotech, talk with @seattletimes about their entrepreneurial journey, with roots starting at Fred Hutch, and the promise of immune medicine bit.ly/3CA440I
Adaptive Biotech retweeted
From me: Two bros who built Lego as kids are now building @AdaptiveBiotech
🔬Their super-blood-test can ID hundreds of millions of immune cells.
🦠 Started with cancer, now also going after Covid.
🏙 Yet another @fredhutch unicorn.
(via @seattletimes)
seattletimes.com/business/se…
Adaptive Biotech retweeted
@AdaptiveBiotech has initiated a research project with Finnish biobanks and @FinbbSuomi to utilize Finnish biobank samples for development and validation of immunosequencing-based clinical testing for autoimmune disorders. site.fingenious.fi/en/articl…
Adaptive Biotech retweeted
We were lucky to have four of these thoughtful, talented people join our computational biology team this summer. If you're interested in joining us next year, it's never too early to start the conversation!
This summer, we had the honor of hosting the next generation of biotech professionals. To all our internship alumni, thank you for your hard work and best of luck on your journeys!
Interested in becoming a future intern? Join the talent community at careers.adaptivebiotech.com.
Adaptive Biotech retweeted
T-cell diagnostic tests. COVID-19 pushed the team @AdaptiveBiotech and they can see more T-cell immunity tests coming. Guest article by CEO Chad Robins. timmermanreport.com/2021/06/…
Adaptive Biotech retweeted
Here @Microsoft @Health_IT the @AdaptiveBiotech folks challenged us to accelerate, dramatically, the work on T-cell based diagnostics in order to help the world respond to #COVID19. We said yes but honestly didn't know if it would be possible. But it was, and here it is.
Today we launched T-Detect™ COVID, the first clinical T cell based test to confirm recent or prior #COVID19 infection. Read more: bit.ly/2ZEo3tA
This use has not been cleared or approved by the FDA.
Adaptive Biotech retweeted
Q² Solutions, an IQVIA & @QuestDX joint venture, announced a partnership with @AdaptiveBiotech to offer customers the immunoSEQ® Assay, expanding Q² Solutions global Immuno-Oncology & #COVID19 comprehensive testing portfolio solutions offered to clients: bit.ly/3ayiRhp
Adaptive Biotech retweeted
Bringing You The Experts! Join us this Friday, Dec. 18 with @Survivor_Corps founder @dianaberrent from 1-2 PM ET for a conversation on Vaccines, Immunity and T- Cells. Questions can be submitted to [email protected]. @AdaptiveBiotech @mayocliniclabs @ManhattanInst
